dtpcrm: Dose Transition Pathways for Continual Reassessment Method

Christina Yap; Daniel Slade; Kristian Brock; Yi Pan

dtpcrm: Dose Transition Pathways for Continual Reassessment Method

Christina Yap, Daniel Slade, Kristian Brock, Yi Pan

Research output: Non-textual form › Software

Abstract

Provides the dose transition pathways (DTP) to project in advance the doses recommended by a model-based design for subsequent patients (stay, escalate, deescalate or stop early) using all the accumulated toxicity information; See Yap et al (2017) <doi:10.1158/1078-0432.CCR-17-0582>. DTP can be used as a design and an operational tool and can be displayed as a table or flow diagram. The 'dtpcrm' package also provides the modified continual reassessment method (CRM) and time-to-event CRM (TITE-CRM) with added practical considerations to allow stopping early when there is sufficient evidence that the lowest dose is too toxic and/or there is a sufficient number of patients dosed at the maximum tolerated dose.

Original language	English
Publication status	Published - 10 Apr 2019

Keywords

R
dtp
crm

Access to Document

https://cran.r-project.org/web/packages/dtpcrm/index.htmlLicence: GNU: Lesser General Public License (LGPL)

Cite this

@misc{eb5305c9dbca47aea16bf2767bf81057,

title = "dtpcrm: Dose Transition Pathways for Continual Reassessment Method",

abstract = "Provides the dose transition pathways (DTP) to project in advance the doses recommended by a model-based design for subsequent patients (stay, escalate, deescalate or stop early) using all the accumulated toxicity information; See Yap et al (2017) . DTP can be used as a design and an operational tool and can be displayed as a table or flow diagram. The 'dtpcrm' package also provides the modified continual reassessment method (CRM) and time-to-event CRM (TITE-CRM) with added practical considerations to allow stopping early when there is sufficient evidence that the lowest dose is too toxic and/or there is a sufficient number of patients dosed at the maximum tolerated dose.",

keywords = "R, dtp, crm",

author = "Christina Yap and Daniel Slade and Kristian Brock and Yi Pan",

year = "2019",

month = apr,

day = "10",

language = "English",

}

TY - ADVS

T1 - dtpcrm

T2 - Dose Transition Pathways for Continual Reassessment Method

AU - Yap, Christina

AU - Slade, Daniel

AU - Brock, Kristian

AU - Pan, Yi

PY - 2019/4/10

Y1 - 2019/4/10

N2 - Provides the dose transition pathways (DTP) to project in advance the doses recommended by a model-based design for subsequent patients (stay, escalate, deescalate or stop early) using all the accumulated toxicity information; See Yap et al (2017) . DTP can be used as a design and an operational tool and can be displayed as a table or flow diagram. The 'dtpcrm' package also provides the modified continual reassessment method (CRM) and time-to-event CRM (TITE-CRM) with added practical considerations to allow stopping early when there is sufficient evidence that the lowest dose is too toxic and/or there is a sufficient number of patients dosed at the maximum tolerated dose.

AB - Provides the dose transition pathways (DTP) to project in advance the doses recommended by a model-based design for subsequent patients (stay, escalate, deescalate or stop early) using all the accumulated toxicity information; See Yap et al (2017) . DTP can be used as a design and an operational tool and can be displayed as a table or flow diagram. The 'dtpcrm' package also provides the modified continual reassessment method (CRM) and time-to-event CRM (TITE-CRM) with added practical considerations to allow stopping early when there is sufficient evidence that the lowest dose is too toxic and/or there is a sufficient number of patients dosed at the maximum tolerated dose.

KW - R

KW - dtp

KW - crm

M3 - Software

ER -

dtpcrm: Dose Transition Pathways for Continual Reassessment Method

Abstract

Keywords

Access to Document

Fingerprint

Cite this